247 related articles for article (PubMed ID: 9180282)
1. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
[TBL] [Abstract][Full Text] [Related]
2. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
4. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
5. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
6. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
Zhou M; Zeng J; Wang X; Guo Q; Huang T; Shen H; Fu Y; Wang L; Jia J; Chen C
J Transl Med; 2013 Oct; 11():265. PubMed ID: 24148180
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
8. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM.
Marley SB; Davidson RJ; Goldman JM; Gordon MY
Leukemia; 2000 Aug; 14(8):1396-400. PubMed ID: 10942234
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
10. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios MB; Talpaz M
Blood; 1999 Jun; 93(12):4149-53. PubMed ID: 10361112
[TBL] [Abstract][Full Text] [Related]
11. [The effect of interferon alone, cytosine arabinoside alone and their combined effect on hematopoietic progenitors of chronic myeloid leukemia in vitro].
Qin H; Yang Y; Liang Y; Li Y; Zeng L
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Apr; 33(2):281-4. PubMed ID: 12575210
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.
Selleri C; Sato T; Del Vecchio L; Luciano L; Barrett AJ; Rotoli B; Young NS; Maciejewski JP
Blood; 1997 Feb; 89(3):957-64. PubMed ID: 9028327
[TBL] [Abstract][Full Text] [Related]
13. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.
Bhatia R; McCarthy JB; Verfaillie CM
Blood; 1996 May; 87(9):3883-91. PubMed ID: 8611716
[TBL] [Abstract][Full Text] [Related]
15. Potent antileukemic activity of the novel agents norsegoline and dibezine.
Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.
Mai WY; Lin MF
Chin Med J (Engl); 2005 Mar; 118(6):487-92. PubMed ID: 15788130
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.
Marley SB; Deininger MW; Davidson RJ; Goldman JM; Gordon MY
Exp Hematol; 2000 May; 28(5):551-7. PubMed ID: 10812245
[TBL] [Abstract][Full Text] [Related]
19. [Vascular endothelial growth factor antisense oligodeoxynucleotide enhance drug-sensitivity of myeloid leukemia cells to homoharringtonine].
Fei J; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):27-30. PubMed ID: 15946505
[TBL] [Abstract][Full Text] [Related]
20. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Korycka A; Robak T
Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]